172 related articles for article (PubMed ID: 27523970)
1. Molecular Evaluation of Colorectal Adenocarcinoma: Current Practice and Emerging Concepts.
Nowak JA; Hornick JL
Surg Pathol Clin; 2016 Sep; 9(3):427-39. PubMed ID: 27523970
[TBL] [Abstract][Full Text] [Related]
2. Pathological complete response with anti-PD-1 therapy in a patient with microsatellite instable high, BRAF mutant metastatic colon cancer: a case report and review of literature.
Sehdev A; Cramer HM; Ibrahim AA; Younger AE; O'Neil BH
Discov Med; 2016 May; 21(117):341-7. PubMed ID: 27355330
[TBL] [Abstract][Full Text] [Related]
3. Pathologic Evaluation of Therapeutic Biomarkers in Colorectal Adenocarcinoma.
Baranov E; Nowak JA
Surg Pathol Clin; 2023 Dec; 16(4):635-650. PubMed ID: 37863556
[TBL] [Abstract][Full Text] [Related]
4. Molecular diagnostics of colorectal cancer.
Bedeir A; Krasinskas AM
Arch Pathol Lab Med; 2011 May; 135(5):578-87. PubMed ID: 21526956
[TBL] [Abstract][Full Text] [Related]
5. Microsatellite instability and colorectal cancer.
Geiersbach KB; Samowitz WS
Arch Pathol Lab Med; 2011 Oct; 135(10):1269-77. PubMed ID: 21970482
[TBL] [Abstract][Full Text] [Related]
6. Simplified identification of Lynch syndrome: a prospective, multicenter study.
Bonnet D; Selves J; Toulas C; Danjoux M; Duffas JP; Portier G; Kirzin S; Ghouti L; Carrère N; Suc B; Alric L; Barange K; Buscail L; Chaubard T; Imani K; Guimbaud R
Dig Liver Dis; 2012 Jun; 44(6):515-22. PubMed ID: 22480969
[TBL] [Abstract][Full Text] [Related]
7. Colorectal poorly differentiated neuroendocrine carcinomas frequently exhibit BRAF mutations and are associated with poor overall survival.
Olevian DC; Nikiforova MN; Chiosea S; Sun W; Bahary N; Kuan SF; Pai RK
Hum Pathol; 2016 Mar; 49():124-34. PubMed ID: 26826419
[TBL] [Abstract][Full Text] [Related]
8. [Colorectal Carcinoma with Suspected Lynch Syndrome: A Multidisciplinary Algorithm].
Schneider R; Schneider C; Büttner R; Reinacher-Schick A; Tannapfel A; Fürst A; Rüschoff J; Jakobeit C; Royer-Pokora B; Möslein G
Zentralbl Chir; 2015 Dec; 140(6):591-9. PubMed ID: 25372301
[TBL] [Abstract][Full Text] [Related]
9. New Therapeutic Opportunities Based on DNA Mismatch Repair and BRAF Status in Metastatic Colorectal Cancer.
Cohen R; Svrcek M; Dreyer C; Cervera P; Duval A; Pocard M; Fléjou JF; de Gramont A; André T
Curr Oncol Rep; 2016 Mar; 18(3):18. PubMed ID: 26861657
[TBL] [Abstract][Full Text] [Related]
10. Epigenetics could explain some Moroccan population colorectal cancers peculiarities: microsatellite instability pathway exploration.
Sekal M; Ameurtesse H; Chbani L; Ouldim K; Bennis S; Abkari M; Boulouz A; Benajah DA; Benjelloun B; Ousadden A; Ait Taleb K; Ait Laalim S; Toghrai I; Mazaz K; Arifi S; Mellas N; El Rhazi K; Harmouch T; Ibrahimi SA; Amarti Riffi A
Diagn Pathol; 2015 Jun; 10():77. PubMed ID: 26104511
[TBL] [Abstract][Full Text] [Related]
11. Screening for Lynch syndrome and referral to clinical genetics by selective mismatch repair protein immunohistochemistry testing: an audit and cost analysis.
Colling R; Church DN; Carmichael J; Murphy L; East J; Risby P; Kerr R; Chetty R; Wang LM
J Clin Pathol; 2015 Dec; 68(12):1036-9. PubMed ID: 26201544
[TBL] [Abstract][Full Text] [Related]
12. The role of microsatellite instability testing in management of colorectal cancer.
Sinicrope FA
Clin Adv Hematol Oncol; 2016 Jul; 14(7):476-9. PubMed ID: 27379941
[No Abstract] [Full Text] [Related]
13. Distinctive patterns of p53 protein expression and microsatellite instability in human colorectal cancer.
Nyiraneza C; Jouret-Mourin A; Kartheuser A; Camby P; Plomteux O; Detry R; Dahan K; Sempoux C
Hum Pathol; 2011 Dec; 42(12):1897-910. PubMed ID: 21665242
[TBL] [Abstract][Full Text] [Related]
14. Molecular biology from bench-to-bedside - which colorectal cancer patients should be referred for genetic counselling and risk assessment.
Jensen LH; Dysager L; Lindebjerg J; Kølvrå S; Byriel L; Crüger DG
Eur J Cancer; 2010 Jul; 46(10):1823-8. PubMed ID: 20417091
[TBL] [Abstract][Full Text] [Related]
15. Feasibility of screening for Lynch syndrome among patients with colorectal cancer.
Hampel H; Frankel WL; Martin E; Arnold M; Khanduja K; Kuebler P; Clendenning M; Sotamaa K; Prior T; Westman JA; Panescu J; Fix D; Lockman J; LaJeunesse J; Comeras I; de la Chapelle A
J Clin Oncol; 2008 Dec; 26(35):5783-8. PubMed ID: 18809606
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of predictive models in daily practice for the identification of patients with Lynch syndrome.
Tresallet C; Brouquet A; Julié C; Beauchet A; Vallot C; Ménégaux F; Mitry E; Radvanyi F; Malafosse R; Rougier P; Nordlinger B; Laurent-Puig P; Boileau C; Emile JF; Muti C; Penna C; Hofmann-Radvanyi H
Int J Cancer; 2012 Mar; 130(6):1367-77. PubMed ID: 21520036
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathologic and molecular characteristics of synchronous colorectal cancers: heterogeneity of clinical outcome depending on microsatellite instability status of individual tumors.
Bae JM; Cho NY; Kim TY; Kang GH
Dis Colon Rectum; 2012 Feb; 55(2):181-90. PubMed ID: 22228162
[TBL] [Abstract][Full Text] [Related]
18. Successful treatment of metastatic colorectal cancer with synchronous
Cheng Y; Fang XF; Hu HG; Wang J; Sun LF; Yuan Y
Immunotherapy; 2020 Mar; 12(4):229-234. PubMed ID: 32172642
[TBL] [Abstract][Full Text] [Related]
19. BRAF p.Val600Glu (V600E) somatic mutation is mainly associated with MSS phenotype in metastatic colorectal cancer.
Qiu J; Compagnone M; Laibe S; Lagarde A; Goncalves A; Turrini O; Xerri L; Monges G; Olschwang S
Cancer Genomics Proteomics; 2011; 8(1):15-8. PubMed ID: 21289333
[TBL] [Abstract][Full Text] [Related]
20. Incorporating traditional and emerging biomarkers in the clinical management of metastatic colorectal cancer: an update.
Baraibar I; Ros J; Mulet N; Salvà F; Argilés G; Martini G; Cuadra JL; Sardo E; Ciardiello D; Tabernero J; Élez E
Expert Rev Mol Diagn; 2020 Jul; 20(7):653-664. PubMed ID: 32552041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
